Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans

Fig. 2

Changes in titers of anti-PAD4 antibodies and anti-PAD4/PAD3 cross-reactive antibodies among CLEAR I RA patients. Only patients who were anti-PAD4-positive (≥0.02 anti-PAD4 antibody IU) at any time (baseline or 36-month disease duration visit) were included (N = 21). Relative titers of anti-PAD4 antibodies (a) and of anti-PAD4 antibodies that cross-react with PAD3 (b) at baseline and 36 months of actual RA disease duration determined by densitometry. Red horizontal line, cutoff between low and high antibody titer. Changes in antibody levels from baseline to 36-month disease duration visit were tested using the Wilcoxon signed rank test, P < 0.05 considered significant. PAD peptidyl arginine deiminase enzyme (Color figure online)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us